Characteristics of CD34-Enriched Products Processed at Multiple Centers Using the CliniMACS System - BMT CTN 0303 (Abstract). In 16th Annual ISCT (International Society for Cellular Therapy) Meeting. presented at the 2010, Philadelphia.. (2010).
Comparative Effectiveness Analysis of CD34+ Selected, T-Cell Depleted (TCD) HLA-Matched Sibling Grafts on Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia (AML) in Complete Remiss (Poster). In BMT Tandem Meeting. presented at the 2010, Orlando, FL.. (2010).
Maximizing Accrual to Transplant Trials in Multiple Myeloma (MM): Lessons from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Eastern Cooperative Oncology Group (ECOG) and Cancer and Leukemia Group B (CALGB) Collaboration (Poster). In NCI ASCO Cancer Trials Accrual Symposium. presented at the 2010, Bethesda, MD.. (2010).
Tacrolimus/Sirolimus vs. Tacrolimus/Methotrexate for GVHD Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of BMT CTN Trial 0402. In 54th Annual ASH Meeting. presented at the 08/12/2012, Atlanta, GA. Retrieved from http://www.hematology.org/Meetings/Annual-Meeting/. (2012).
Etanercept, Mycophenolate, Denileukin, or Pentostatin Plus Corticosteroids for Acute Graft-Versus-Host Disease: A Randomized Phase 2 Trial from the Blood and Marrow Transplant Clinical Trials Network. Blood, 114, 511-517. presented at the 07/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19443659. (2009).
Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT. Blood, 124, 1372-1377. presented at the 08/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24982504. (2014).